Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

225
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
225
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

273
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
273
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

833
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
833
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

256
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
256
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

973
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
973
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

301
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
301

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phenotyping to predict 12-month health outcomes of older general medicine patients.

Aging clinical and experimental research·2025
Same author

Generation of TWO iPSC lines (CRICKi009-A; CRICKi010-A) from patients with type 1 von Hippel-Lindau (VHL) and histopathologically confirmed renal cell carcinoma (RCC).

Stem cell research·2024
Same author

A Retrospective Analysis of Characteristics Favouring In-Hospital Resuscitation Plan Completion, Their Timing, and Associated Outcomes.

Journal of clinical medicine·2024
Same author

Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Screening for End-of-Life in Acute Hospitals: A Cross-Sectional Survey.

The American journal of hospice & palliative care·2024
Same author

A comprehensive characterisation of phaeochromocytoma and paraganglioma tumours through histone protein profiling, DNA methylation and transcriptomic analysis genome wide.

Clinical epigenetics·2023

Related Experiment Video

Updated: Feb 24, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.1K

Short-term changes in liver tests predict long-term mortality.

Eliana Saffouri1, Eugénie S Lim2, Susan W Kim3

  • 1Department of Gastroenterology, Forth Valley Royal Hospital, NHS Forth Valley, Lambert, Scotland, UK.

Frontline Gastroenterology
|August 26, 2017
PubMed
Summary

Short-term changes in liver tests, particularly albumin and alanine aminotransferase (ALT), predict 12-month mortality better than single values. A decreasing albumin level indicates a high risk of death within one year.

Keywords:
CARDIOVASCULAR DISEASECHRONIC LIVER DISEASEELDERLY

More Related Videos

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH
07:13

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Published on: April 20, 2021

4.6K
Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration
05:25

Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration

Published on: May 24, 2024

3.7K

Related Experiment Videos

Last Updated: Feb 24, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.1K
Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH
07:13

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Published on: April 20, 2021

4.6K
Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration
05:25

Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration

Published on: May 24, 2024

3.7K

Area of Science:

  • Internal Medicine
  • Clinical Pathology
  • Prognostic Biomarkers

Background:

  • Liver function tests are commonly used to assess liver health.
  • Predicting long-term mortality in hospitalized patients is crucial for clinical management.

Purpose of the Study:

  • To evaluate if short-term changes in liver tests predict 12-month mortality.
  • To identify the most informative liver test for mortality prediction.

Main Methods:

  • Retrospective review of non-elective general medicine inpatients (minimum 7-day stay).
  • Exclusion of patients with liver disease, malignancy, ICU admission, or inpatient mortality.
  • Logistic regression analysis of admission and intra-admission changes in liver tests, adjusted for covariates.

Main Results:

  • 12-month mortality was 17% in 4160 analyzed patients.
  • Intra-admission changes in albumin and ALT significantly predicted mortality.
  • Intra-admission changes were superior to admission values for mortality prediction.

Conclusions:

  • Changes in liver tests offer superior prognostic information compared to single values.
  • Albumin is a better predictor of long-term mortality than transaminases in the absence of liver disease.
  • Short-term albumin decrease signals high 1-year mortality risk, even from a normal baseline.